ReviewFrontiers in immunology2026
Gut barrier-microbiota crosstalk in sepsis: from pathogenesis to potential therapies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a systemic inflammatory response syndrome triggered by infection, frequently complicated by severe organ dysfunction and high mortality rates. Recent studies of intestinal epithelial function and the gut microbiota have highlighted their pivotal roles in the pathogenesis of sepsis. However, the precise mechanisms governing the interaction between the intestinal epithelium and gut microbiota, and how this interaction drives sepsis progression, still need to be elucidated. In this review, the functions of the intestinal epithelial barrier are first outlined, and the clinical significance of its altered permeability during sepsis is highlighted. Then, the physiological roles of the gut microbiota are further explored, detailing how dysbiosis and microbial metabolites influence disease progression and trigger both localized and systemic immune responses. Based on this, a logical framework for gut-originated systemic inflammation is proposed, and the potential adverse effects of current clinical supportive therapies on intestinal integrity are further discussed. Finally, the emerging sepsis treatment strategies that target gut function are summarized, aiming to provide novel insights and therapeutic directions for clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.